Reported a net loss of $2,459,800 for the three months ended March 31, 2026, compared to a $3,286,022 loss in the same period of 2025. Revenue for the quarter was $161, a significant decline from $106,207 in Q1 2025, attributed to a strategic shift from healthcare-adjacent applications to industrial deployments. Cash and cash equivalents increased to $2,841,422 as of March 31, 2026, up from $417,353 at year-end 2025. Operating expenses decreased by 30% to $2,283,045, driven by lower share-based compensation and reduced administrative costs. Secured a new loan agreement with related party ASE Test, Inc. for approximately $2.81 million (NT$90 million) on March 27, 2026.